المؤلفون: Dipartimento D'emergenza, S Giovanni Addolorata, Roma ¿ Dipartimento D'emergenza, Policlinico Tor Vergata, Pronto Soccorso, Policlinico Casilino, S Camillo -Forlanini, Ospedale S Pertini, Asl Rmb, Valli, Gabriele, Romito, Anna, Susi ¿ Beniamino, Pagnanelli, Adolfo, Sabetta, Francesco, Mirante, Enrico, Bertazzoni, Giuliano, Franceschi, Francesco, Bonfini Rita, Valeriano, Valentina, Timpone, Sergio, Fabiana, Di Ssa, Girolamo, Angelini, Daniele, Romanelli, Antonio, Guglielmelli, Massimo, Ruggieri, Maria Pia, Pugliese, Francesco

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::659c9dd031972b5014606d4c7c58505eTest

المؤلفون: Alessandra Di Pucchio, Roberta Pacifici, Simona Pichini, Antonella Bacosi, Simonetta Di Carlo, Rita Di Giovannandrea, Patrizia Gori, Enrica Pizzi e Gruppo Servizi Territoriali per la cessazione dal fumo di tabacco: Abrami M. A. (ASL Brescia, Leno -BS), Agus A., Nicolazzi L. (ASS2 Isontina, Gorizia), Ameglio M., Cincinelli B. (AUSL 7, Zona Alta Val d'Elsa, Siena), Badii F., Grossi S. (ASL 2 Savonese, Savona), Baraldo M. (OU S. Maria della Misericordia, Udine), Barbano G., Bazzerla G. (AULSS 9 - Ospedale Cà Foncello, Treviso), Bassini M. , Giampaolo R. (AUSL di Modena -Distretto di Castelfranco Emilia -MO), Beato E., Prestipino A. (Dipartimento Dipendenze, ASL di Bergamo), Bergozza L. , Rossetto L. (ULSS 4 Thiene -VI), Bertoletti R. (AO Valtellina e Valchiavenna, Sondalo), Biasin C., Manzato E. (ULSS 21, Zevio -VR), Bigarelli M. (AUSL Modena Area Nord ,Carpi -MO), Bini L. (ASL della Provincia di Mantova), Boffi R., Pozzi P. (Fondazione IRCCS Istituto Nazionale dei Tumori, Milano), Brancaccio L., Guarino C. (AO “V. Monaldi”, Napoli), Cacaci C., Apolloni P. (ASUR Marche - Area Vasta 5, San Benedetto del Tronto -AP), Calcagni A. M., Mecozzi L. (Area Vasta 4 - Regione Marche, Porto S. Giorgio -FM), Calzolari U., Rovetta M. (ASL di Bergamo, Lovere -BG), Campiotti A. (ASL Milano 1, Magenta -MI), Canneti E., Saccocci M., Vichi S. (USL 9 P. O. Misericordia, Grosseto), Canzian G. , Russo A. (ASS 3 Alto Friuli), Cao A. (ASL 5, Oristano), Carnevale E. (ASL Napoli 1 Centro - PS “S. Maria di Loreto Crispi”, Napoli), Carone M., Sarno N. (Fondazione S. Maugeri, Cassano delle Murge -BA), Carrozzi L., Pistelli F., Cavalleri C., Pini D. (ASL TO3, Beinasco -TO), Cerrato P. (ASL TO2, Torino), Cestaro C. , Repetto T. (AUSL Valle d'Aosta), Ciarfeo Purich R. , Vegliach A. (ASS 1 Triestina), Cifiello S. (Ausl di Imola), Colombari P., Conti P. (ASL VC, Vercelli), Conterio P., Gallo E. (Asl TO1 Ospedale Martini, Torino), Cordioli E., Melchiori S. (Az. ULSS 22 Bussolengo, Verona), Corti M. (ASL provincia Bergamo, Treviglio -BG), Costantino A. (AO Pugliese Ciaccio, Catanzaro), Cuccagna P., Potosnjack A. (Asl TO3, Perosa Argentina -TO), Cutrì R., Barbanti A. (Azienda 10 Lungarno Santa Rosa, Firenze), D’Urso B., Amendola D. (AOU “OO. RR. San Giovanni di Dio Ruggi D’Aragona”, Salerno), Da Ros D. (ULSS 16, Padova), D'Alessandro V. (IRCCS Ospedale, Dalla Pietra G. , Pavani V. (Az. ULSS 18 Rovigo), De Benedetto F., Manigrasso M. R. (ASL Chieti PO Clinicizzato S. S. Annunziata, Chieti Scalo -CH), De Donno G. (AO Carlo Poma, Mantova), De Lozzo L. , Facchini F. (PO di Vittorio Veneto -TV), De Marchi C. (ASL BI, Cossato -BI), De Siena A. (Sert Lamezia Terme), De Stefano C. (ASP Reggio Calabria), Del Donno M., Romano A. (AO “G. Rummo”, Benevento), Delfini M. , Galati A. (P. O. Villa Betania RM E), Di Dio S., Franco R. (ASP 3 Catania, Giarre -CT), Dominici F. , De Rose V. (ASL di Viterbo), Donateo L. , Gerardi R. (ASL Lecce), Fagni F., Pellegrini V. (AUSL 3 di Pistoia, Pescia -PT), Foschino Barbaro M. P., Ruggieri C. (AOU Policlinico- Ospedale D'Avanzo, Foggia), Fulgione C., Mallardo M. (ASL NA 1 O S. Gennaro, Fusconi E., Del Brocco D. (ASL RMC Distretto 9, Roma), Galletti F., De Palma D. (AOU Federico II, Grammatico P. (ASL Roma D, Roma), Grandelis C. (APSS, Borgo Valsugana -TN), Groppi C. (ASL 3, Pistoia), Iacoacci C. , Barbieri F. (INRCA di Ancona), Ianniello F., Passeri A. (AUSL 8, Montevarchi -AR), Janiri L. (Università Cattolica Sacro Cuore, Roma), Kashanpour H., Zanon D. (ASS 4, Udine), Kugler E. (PO Sud-Ospedale di Gaeta -LT), Lauro G. , D'Amore A. (ASL Caserta), Lavacchini G., Grati D. (ASL 10 FI, Zona Mugello, Borgo S. Lorenzo -FI), Leonardi C., Fierro G. (ASL RMC, Leonetti A. (ASL CN1, Mondovì -CN), Lugoboni F., Casari R. (AO Universitaria, Madonia G. (ARNAS Ospedale Civico di Palermo), Magnelli F. , Rota A. G. (ASP di Cosenza), Maiella D., Izzo A. (ASL BN1, Manfredi A. , Gai P. (ASL 4 di Prato), Mantovani A. , Finessi A. (Az. Ulss 19 Adria -RO), Mantovani R. , Viviani U. (AUSL di Ferrara PO di Copparo -FE), Marino G. (ASP Trapani PO Mazara del Vallo -TP), Marras T. (ASL Sassari), Marsili R. (ASL Ferrara), Melica V. E. (ULSS 13 Dolo -VE), Messere C. (ASL NA2 Nord, Napoli), Monti M. (Istituto Ortopedico Rizzoli, Bologna), Mussoni C. , Cavicchi C. (Az. USL Bologna), Natoli A., Furlan N. (ASS 6, Pordenone), Pamerani B. , Porciatti C. (AUSL 10 Firenze), Panzanella C. (ASL Napoli 1 Centro – Osp “San Giovanni Bosco”, Napoli), Paolin C. , Cannarsa F. (Az. Ulss 7 Pieve di Soligo -TV), Parillo T. , Hazra C. (ASL di Como), Pasinato M. G. (Ulss 8 Asolo, Castelfranco Veneto -TV), Peana G. (ASL 1 Distretto di Alghero -SS), Pellegrini L., Gios L., Herzog S. (Distretto Centro Sud, Rovereto -TN), Perillo A., Ambrosino M. (ASL Na 3 Sud, Pomigliano d'Arco -NA), Perna M. T. (Azienda Sanitaria di Matera), Pezzuto A., Mariotta S. (AO S. Andrea- Università Sapienza, Piancastelli G., Ricci C., Fabbri C., Fava P. (Az. USL Ravenna, Sedi di Ravenna, Bagnacavallo, Faenza -RA), Pieralli D., Ferrarotto E. (AUSL 8 Zona Aretina, Arezzo), Pistelli R., Villani A. (Università Cattolica, Complesso Integrato Columbus, Polo M. F., Manca S. (AOU, Sassari), Polosa R., Caponnetto P. (AOU, Università di Catania), Principe R. Clementi F., Dragani L. (AO S. Camillo-Forlanini, Pulerà N. (AUSL 6, Livorno), Puoti F. (ASL Na1, Napoli), Residori M. (AULSS 22 Regione Veneto, Villafranca -VR), Romagnolo A. (ASL AT, Asti), Romano A., Russo G., Arimatea S. (ASL TO 4 Ivrea, Chivasso, Ciriè -TO), Romano F. , Scarlato M. I. (AO di Cosenza), Sacchi G., Magro F. (ASL 1-Poliambulatorio “U. Alletto”, Agrigento), Saetta M., Forza G., Balestro E. (PO di Padova), Serafini A., Bertora G. (Ospedale Civile, Imperia), Siracusano L., Autuori M. (Istituto Clinico Humanitas, Rozzano -MI), Spada E., Balestroni G. (Fondazione S. Maugeri, Veruno -NO), Staccioli M. C. , Rossi B. (Ausl Rimini), Stefano V., Gaggini R. (ASL Provincia di Varese, Arcisate -VA), Subiaco S., Cimarelli M. E. (ASUR Marche, Area Vasta 2 Jesi -AN), Tartarotti I. (APSS, Pergine -TN), Tavanti G., Paparini L. (AUSL 10, Antella -FI), Tinghino B. (ASL Provincia di Monza e Brianza, Monza), Trapani V. (ASP N9 Trapani), Triani A. , Senoner A. (AS Merano e AS Bolzano -BZ), Valeri W. (Area Vasta 2 Ancona – ASUR Marche, Ancona), Varango C. (ASL di Lodi), Varese M. (ASL 1, Regione Toscana), Vidal V., Mustacchi A. (ASS 5, Palmanova -UD), Viola S., Tomasich A. (A. O. Salvini, Garbagnate -MI), Virzì G. (AO Istituti Ospitalieri di Cremona -CR), Vito A., Parrella R. (AORN Ospedali dei Colli Monaldi-Cotugno-C. T. O., Zagà V. (AUSL di Bologna), Zini G. (ULSS 5

المساهمون: Alessandra Di, Pucchio, Roberta, Pacifici, Simona, Pichini, Antonella, Bacosi, Simonetta Di, Carlo, Rita Di, Giovannandrea, Patrizia, Gori, Enrica Pizzi e Gruppo Servizi Territoriali per la cessazione dal fumo di tabacco: Abrami M. A., (ASL Brescia, Leno, -BS), Agus, A., Nicolazzi L., (ASS2 Isontina, Gorizia), Ameglio, M., Cincinelli B., (AUSL 7, Zona Alta Val, D'Elsa, Siena), Badii, F., Grossi S., (ASL 2 Savonese, Savona), Baraldo M. (OU S. Maria della Misericordia, Udine), Barbano, G., Bazzerla G., (AULSS 9 - Ospedale Cà Foncello, Treviso), Bassini M., Giampaolo R. (AUSL di Modena -Distretto di Castelfranco Emilia -MO), Beato, E., Prestipino A., (Dipartimento Dipendenze, ASL di, Bergamo), Bergozza L., Rossetto L. (ULSS 4 Thiene -VI), Bertoletti R. (AO Valtellina e Valchiavenna, Sondalo), Biasin, C., Manzato E., (ULSS 21, Zevio, -VR), Bigarelli M. (AUSL Modena Area Nord, Carpi -MO), Bini L., (ASL della Provincia di Mantova), Boffi, R., Pozzi P., (Fondazione IRCCS Istituto Nazionale dei Tumori, Milano), Brancaccio, L., Guarino C. (AO “V., Monaldi”, Napoli), Cacaci, C., Apolloni P., (ASUR Marche - Area Vasta 5, San Benedetto del Tronto, -AP), Calcagni, A. M., Mecozzi L., (Area Vasta 4 - Regione Marche, Porto S., Giorgio -FM), Calzolari, U., Rovetta M., (ASL di Bergamo, Lovere, -BG), Campiotti A. (ASL Milano 1, Magenta -MI), Canneti, E., Saccocci, M., Vichi S. (USL 9 P. O., Misericordia, Grosseto), Canzian G., Russo A. (ASS 3 Alto Friuli), Cao A. (ASL 5, Oristano), Carnevale E. (ASL Napoli 1 Centro - PS “S. Maria di Loreto Crispi”, Napoli), Carone, M., Sarno N. (Fondazione S., Maugeri, Cassano delle Murge, -BA), Carrozzi, L., Pistelli, F., Cavalleri, C., Pini D., (ASL TO3, Beinasco, -TO), Cerrato P. (ASL TO2, Torino), Cestaro C., Repetto T. (AUSL Valle d'Aosta), Ciarfeo Purich R., Vegliach A. (ASS 1 Triestina), Cifiello S., (Ausl di Imola), Colombari, P., Conti P., (ASL VC, Vercelli), Conterio, P., Gallo E., (Asl TO1 Ospedale Martini, Torino), Cordioli, E., Melchiori S. (Az., ULSS 22 Bussolengo, Verona), Corti M. (ASL provincia Bergamo, Treviglio -BG), Costantino A. (AO Pugliese Ciaccio, Catanzaro), Cuccagna, P., Potosnjack A., (Asl TO3, Perosa Argentina, -TO), Cutrì, R., Barbanti A., (Azienda 10 Lungarno Santa Rosa, Firenze), D’Urso, B., Amendola D. (AOU “OO. RR., San Giovanni di Dio Ruggi D’Aragona”, Salerno), Da Ros D. (ULSS 16, Padova), D'Alessandro V., (IRCCS Ospedale, Dalla Pietra G., Pavani V. (Az. ULSS 18 Rovigo), De Benedetto, F., Manigrasso M. R. (ASL Chieti PO Clinicizzato S. S., Annunziata, Chieti Scalo, -CH), De Donno G. (AO Carlo Poma, Mantova), De Lozzo L., Facchini F. (PO di Vittorio Veneto -TV), De Marchi C. (ASL BI, Cossato -BI), De Siena A., (Sert Lamezia Terme), De Stefano C., (ASP Reggio Calabria)

مصطلحات موضوعية: Centri Antifumo, Indagine on-line, Cessazione dal fumo di tabacco, Fumo di tabacco

الوصف: Introduzione. In Italia sono 295 i Servizi per la cessazione dal fumo di tabacco (Centri Antifumo - CA) afferenti al Servizio Sanitario Nazionale (SSN) censiti nel 2011 dall’Osservatorio Fumo, Alcol e Droga (OssFAD) dell’Istituto Superiore di Sanità. La presente indagine, condotta dall’OssFAD in collaborazione con i CA, è stata volta a rilevare alcune delle problematiche con le quali il personale dei CA si confronta per portare avanti la propria attività e le iniziative ritenute utili per migliorarla. Materiali e metodi. L’indagine è stata condotta dal 7 al 21 maggio 2012, mediante un questionario compilabile on-line composto da 5 brevi sezioni di domande con un totale di 38 items da completare. Il link al questionario on-line è stato inviato per e-mail a 322 indirizzi dei CA censiti nel 2011 dall’OssFAD. I dati raccolti sono stati elaborati statisticamente con il programma SPSS 20. Risultati. All’indagine hanno risposto 146 operatori dei CA (45,3%). Sebbene ci siano aspetti ormai consolidati dell’attività dei CA, sono ancora molte le criticità che gli operatori riscontrano nella loro attività. Le principali problematiche che influiscono in modo fondamentale/rilevante per la buona attività del centro sono le “Scarse o nulle risorse economiche” per il 60,7% del personale, “la mancanza di personale dedicato” per il 52,4% del personale; il “riconoscimento/mandato istituzionale del CA” per il 40,9% del personale. Tra le azioni ritenute più efficaci per facilitare l’accesso ai CA sono risultate la sensibilizzazione del personale sanitario (91%), in particolare dei medici di famiglia e l’inserimento delle prestazioni antitabagiche nei LEA (76,8%). Conclusioni. È auspicabile che l’attività dei CA riceva una maggiore attenzione, attraverso la dotazione di strutture, personale e finanziamenti adeguati a svolgere un importante ruolo nella tutela e promozione della salute.

وصف الملف: ELETTRONICO

العلاقة: volume:1; firstpage:22; lastpage:29; numberofpages:8; journal:TABACCOLOGIA; http://hdl.handle.net/11568/1121971Test; https://www.tabaccologia.it/PDF/Tabaccologia_01-13.pdfTest

الإتاحة: http://hdl.handle.net/11568/1121971Test
https://www.tabaccologia.it/PDF/Tabaccologia_01-13.pdfTest

المؤلفون: Bron, Guillaume, Scemama, Ugo, Villes, Virginie, Fakhry, Nicolas, Salas, Sebastien, Chagnaud, Christophe, Bendahan, David, Varoquaux, Arthur

المساهمون: EVEHA (Etudes et valorisations archeologiques), Hôpital Nord CHU - APHM, Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Conception CHU - APHM (LA CONCEPTION), Medical Oncology Unit, S. Camillo-Forlanini Hospital, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)

المصدر: ISSN: 1368-8375 ; Oral Oncology ; https://hal.science/hal-02426089Test ; Oral Oncology, 2019, 94, pp.41-46. ⟨10.1016/j.oraloncology.2019.04.023⟩.

مصطلحات موضوعية: [SDV.IB]Life Sciences [q-bio]/Bioengineering

الوصف: International audience

العلاقة: hal-02426089; https://hal.science/hal-02426089Test; https://hal.science/hal-02426089/documentTest; https://hal.science/hal-02426089/file/S1368837519301356.pdfTest; PII: S1368-8375(19)30135-6

الإتاحة: https://doi.org/10.1016/j.oraloncology.2019.04.023Test
https://hal.science/hal-02426089Test
https://hal.science/hal-02426089/documentTest
https://hal.science/hal-02426089/file/S1368837519301356.pdfTest

المؤلفون: Estienne, Laura, Dany, Lionel, Dudoit, Eric, Duffaud, Florence, Salas, Sebastien

المساهمون: Laboratoire de Psychologie Sociale (LPS), Aix Marseille Université (AMU), Service d’Oncologie Médicale Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone CHU - APHM (TIMONE), Medical Oncology Unit, S. Camillo-Forlanini Hospital

المصدر: ISSN: 1778-3798.

مصطلحات موضوعية: Spirituality, Cancer, Coping, Livedexperience, Spiritualité, Expérience vécue, [SHS]Humanities and Social Sciences, [SHS.PSY]Humanities and Social Sciences/Psychology

الوصف: International audience ; Aims: Patients suffering from cancer are often confronted with an awareness of their own finiteness and with the fact that their life is now ruled by the cancer. This existential upheaval can be accompanied by spiritual “work” which contributes to the adjustment to the disease and to the conditions of the end of life. Spirituality can be defined as a process through which individuals seek for and give meaning to their life, feel connected to the self, to others, at the present moment and in what is sacred. Few studies in France have studied spirituality in the context of cancer. So, the aim of our research was to identify and to study the role of spiritual components in the experience of cancer.Procedure: We carried out 15 semi-directed interviews with patients at the medical oncology and palliative care department at the CHU in Timone (Marseille). A double analysis was performed: 1) a lexicographical analysis and 2) a thematic content analysis of the most typical interviews from the lexicographical analysis.Results: The lexicographical analysis highlighted three lexical classes. Class 1 represented the illness of cancer as a personal transformation (40.5%), Class 2 concerned the biographical disruption experience (13.4%) and Class 3 corresponded to daily life with the illness (46.1%). Moreover, the thematic content analysis revealed different themes testifying to spirituality in the lived experience of cancer, in particular the experience of and the relationship with the sacred, the relationship with transcendence and the role of spirituality in the lived experience of patients who are suffering from cancer.Conclusion: The two analyses of the interviews allowed us to identify the expression of spirituality. Spirituality was expressed as a resource, an “invisible spring,” allowing people to adjust to the extreme experience of the disease of cancer. Both “secular” and “central” dimensions of spirituality: the transcendence and the relationship with the sacred open perspectives for the ...

العلاقة: hal-02527315; https://amu.hal.science/hal-02527315Test; https://amu.hal.science/hal-02527315/documentTest; https://amu.hal.science/hal-02527315/file/Manuscript%20r%C3%A9vis%C3%A9.pdfTest

الإتاحة: https://doi.org/10.3166/pson-2019-0105Test
https://amu.hal.science/hal-02527315Test
https://amu.hal.science/hal-02527315/documentTest
https://amu.hal.science/hal-02527315/file/Manuscript%20r%C3%A9vis%C3%A9.pdfTest

المؤلفون: Becher, Francois, Ciccolini, Joseph, Imbs, Diane-Charlotte, Marin, Clemence, Fournel, Claire, Dupuis, Charlotte, Fakhry, Nicolas, Pourroy, Bertrand, Ghettas, Aurelie, Pruvost, Alain, Junot, Christophe, Duffaud, Florence, Lacarelle, Bruno, Salas, Sebastien

المساهمون: Groupe de Pharmacologie Clinique & Oncologique (GPCO), UNICANCER, Laboratoire d'Etudes et de Recherches en Immunoanalyses (LERI), Service de Pharmacologie et Immunoanalyse (SPI), Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay-Institut des Sciences du Vivant Frédéric JOLIOT (JOLIOT), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Paris-Saclay-Institut des Sciences du Vivant Frédéric JOLIOT (JOLIOT), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Médicaments et Technologies pour la Santé (MTS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut National de la Recherche Agronomique (INRA), Simulation & Modelling : Adaptive Response for Therapeutics in Cancer (SMARTc unit), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)-Hôpital de la Timone CHU - APHM (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Hôpital de la Timone CHU - APHM (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM), Medical Oncology Unit, S. Camillo-Forlanini Hospital, Hôpital de la Timone CHU - APHM (TIMONE), Hôpital de la Conception CHU - APHM (LA CONCEPTION), Oncopharma, Université Paris-Saclay, AM*IDEX project (MARS Project, Aix Marseille Univ.), Investissement d'Avenir French government program, ANR-11-IDEX-0001,Amidex,INITIATIVE D'EXCELLENCE AIX MARSEILLE UNIVERSITE(2011)

المصدر: ISSN: 2045-2322.

مصطلحات موضوعية: oral cancer, translational research, [SDV]Life Sciences [q-bio]

الوصف: Administration of first-in-class anti-EGFR monoclonal antibody cetuximab is contingent upon extensive pharmacogenomic testing. However in addition to tumor genomics, drug exposure levels could play a critical, yet largely underestimated role, because several reports have demonstrated that cetuximab pharmacokinetic parameters, in particular clearance values, were associated with survival in patients. Here, we have developed an original bioanalytical method based upon the use of LC-MS/MS technology and a simplified sample preparation procedure to assay cetuximab in plasma samples from patients, thus meeting the requirements of standard Therapeutic Drug Monitoring in routine clinical practice. When tested prospectively in a pilot study in 25 head-and-neck cancer patients, this method showed that patients with clinical benefit had cetixumab residual concentrations higher than non-responding patients (i.e., 49 +/- 16.3 mu g/ml VS. 25.8 +/- 17 mu g/ml, p < 0.01 t test). Further ROC analysis showed that 33.8 mu g/ml was the Cmin threshold predictive of response with an acceptable sensitivity (87%) and specificity (78%). Mass spectrometry-based therapeutic drug monitoring of cetuximab in head-and-neck cancer patients could therefore help to rapidly predict cetuximab efficacy and to adapt dosing if required.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28578404; hal-01606760; https://hal.science/hal-01606760Test; https://hal.science/hal-01606760/documentTest; https://hal.science/hal-01606760/file/Becher-2017-scientific-report_1.pdfTest; PRODINRA: 404955; PUBMED: 28578404; WOS: 000402515800032

الإتاحة: https://doi.org/10.1038/s41598-017-02821-xTest
https://hal.science/hal-01606760Test
https://hal.science/hal-01606760/documentTest
https://hal.science/hal-01606760/file/Becher-2017-scientific-report_1.pdfTest

المؤلفون: Cuomo, Barbara, Cosimo Indirli, Giovanni, Bianchi, Annamaria, Arasi, Stefania, Caimmi, Davide, Dondi, Arianna, Grutta, Stefania, Panetta, Valentina, Verga, Maria, Calvani, Mauro

المساهمون: Belcolle Hospital, Ospedale San Giuseppe da Copertino, S. Camillo-Forlanini Hospital, University of Messina, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dipartimento Salute della Donna, del Bambino e dell'Adolescente, Policlinico S.Orsola-Malpighi, Istituto di Biomedicina ed Immunologia Molecolare “Alberto Monroy”, National Research Council of Italy

المصدر: ISSN: 1720-8424.

مصطلحات موضوعية: [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition

الوصف: International audience ; Background: The diagnosis of IgE-mediated cow’s milk allergy is often based on anamnesis, and on specific IgE (sIgE) levels and/or Skin Prick Tests (SPT), which have both a good sensitivity but a low specificity, often causing positive results in non-allergic subjects. Thus, oral food challenge is still the gold standard test for diagnosis, though being expensive, time-consuming and possibly at risk for severe allergic reactions.Aim: The aim of the present study was to perform a systematic review of the studies that have so far analyzed the positive predictive values for sIgE and SPT in the diagnosis of allergy to fresh and baked cow’s milk according to age, and to identify possible cut-offs that may be useful in clinical practice.Methods: A comprehensive search on Medline via PubMed and Scopus was performed August 2017. Studies were included if they investigated possible sIgE and/or SPT cut-off values for cow’s milk allergy diagnosis in pediatric patients. The quality of the studies was evaluated according to QUADAS-2 criteria.Results: The search produced 471 results on Scopus, and 2233 on PubMed. Thirty-one papers were included in the review and grouped according to patients’ age, allergen type and cooking degree of the milk used for the oral food challenge.In children < 2 years, CMA diagnosis seems to be highly likely when sIgE to CM extract are ≥ 5 KUA/L or when SPT with commercial extract are above 6 mm or Prick by Prick (PbP) with fresh cow’s milk are above 8 mm. Any cut-offs are proposed for single cow’s milk proteins and for baked milk allergy in children younger than 2 years. In Children ≥ 2 years of age it is hard to define practical cut-offs for allergy to fresh and baked cow’s milk. Cut-offs identified are heterogeneous.Conclusions: None of the cut-offs proposed in the literature can be used to definitely confirm cow’s milk allergy diagnosis, either to fresh pasteurized or to baked milk. However, in children < 2 years, cut-offs for specific IgE or SPT seem to be more ...

العلاقة: hal-01626798; https://hal.sorbonne-universite.fr/hal-01626798Test; https://hal.sorbonne-universite.fr/hal-01626798/documentTest; https://hal.sorbonne-universite.fr/hal-01626798/file/document1.pdfTest

الإتاحة: https://doi.org/10.1186/s13052-017-0410-8Test
https://hal.sorbonne-universite.fr/hal-01626798Test
https://hal.sorbonne-universite.fr/hal-01626798/documentTest
https://hal.sorbonne-universite.fr/hal-01626798/file/document1.pdfTest

المؤلفون: Biancari, Fausto, Tauriainen, Tuomas, Perrotti, Andrea, Dalén, Magnus, Faggian, Giuseppe, Franzese, Ilaria, Chocron, Sidney, Ruggieri, Vito G., Bounader, Karl, Gulbins, Helmut, Reichart, Daniel, Svenarud, Peter, Santarpino, Giuseppe, Fischlein, Theodor, Puski, Tamas, Maselli, Daniele, Dominici, Carmelo, Nardella, Saverio, Gherli, Riccardo, Musumeci, Francesco, Rubino, Antonino S., Mignosa, Carmelo, de Feo, Marisa, Bancone, Ciro, Gatti, Giuseppe, Maschietto, Luca, Santini, Francesco, Salsano, Antonio, Nicolini, Francesco, Gherli, Tiziano, Zanobini, Marco, Saccocci, Matteo, d'Errigo, Paola, Kinnunen, Eeva-Maija, Onorati, Francesco

المساهمون: Oulu University Hospital Oulu, Service de Chirurgie Cardiaque CHU Besançon, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Karolinska Institutet Stockholm, University Hospital of Verona, CHU Pontchaillou Rennes, University Heart Center Hamburg, Karolinska University Hospital Stockholm, Paracelsus Medizinische Privatuniversität = Paracelsus Medical University (PMU), St Anna Hospital, S. Camillo-Forlanini Hospital, Morgagni-Pierantoni Hospital, University of Naples Federico II = Università degli studi di Napoli Federico II, Ospedali Riuniti, Università degli studi di Genova = University of Genoa (UniGe), Università degli studi di Parma = University of Parma (UNIPR), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Superiore di Sanità (ISS)

المصدر: ISSN: 1743-9191.

مصطلحات موضوعية: Cardiac surgery, Transfusion, Stroke, Coronary artery bypass surgery, Coronary artery bypass grafting, Bleeding, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: International audience ; INTRODUCTION: This study was planned to investigate the impact of severe bleeding and blood transfusion on the development of stroke after coronary surgery.METHODS: This cohort study includes 2357 patients undergoing isolated CABG from the prospective European Coronary Artery Bypass Grafting (E-CABG) registry. Severity of bleeding was categorized according to the Universal Definition of Perioperative Bleeding (UDPB), E-CABG and PLATO definitions.RESULTS: Thirty patients (1.3%) suffered postoperative stroke. The amount of transfused red blood cell (RBC) (OR 1.10, 95%CI 1.03-1.18), preoperative use of unfractioned heparin (OR 4.49, 95%CI 1.91-10.60), emergency operation (OR 3.97, 95%CI 1.47-10.74), diseased ascending aorta (OR 4.62, 95%CI 1.37-15.65) and use of cardiopulmonary bypass (p = 0.043, OR 4.85, 95%CI 1.05-22.36) were independent predictors of postoperative stroke. Adjusted analysis showed that UDPB classes 3-4 (crude rate: 3.6% vs. 1.0%; adjusted OR 2.66, 95%CI 1.05-6.73), E-CABG bleeding grades 2-3 (crudes rate: 6.3% vs. 0.9%; adjusted OR 5.91, 95%CI 2.43-14.36), and PLATO life-threatening bleeding (crude rate: 2.5% vs. 0.6%, adjusted OR 3.70, 95%CI 1.59-8.64) were associated with an increased risk of stroke compared with no or moderate bleeding.CONCLUSIONS: Bleeding and blood transfusion are associated with an increased risk of stroke after CABG, which is highest in patients with severe bleeding.

العلاقة: hal-01593109; https://hal-univ-rennes1.archives-ouvertes.fr/hal-01593109Test; https://hal-univ-rennes1.archives-ouvertes.fr/hal-01593109/documentTest; https://hal-univ-rennes1.archives-ouvertes.fr/hal-01593109/file/Bleeding,%20Transfusion%20and%20the%20Risk%20of%20Stroke.pdfTest

الإتاحة: https://doi.org/10.1016/j.ijsu.2016.06.032Test
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01593109Test
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01593109/documentTest
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01593109/file/Bleeding,%20Transfusion%20and%20the%20Risk%20of%20Stroke.pdfTest

المؤلفون: Jean-Yves Blay, Charles Honoré, Marick Laé, Audrey Monneur, Mehdi Brahmi, Fabien Reyal, Nicolas Isambert, Camille Chakiba, Esma Saada-Bouzid, Sophie Piperno-Neumann, Thomas Ryckewaert, Nelly Firmin, S. Thezenas, Christophe Sajous, Nicolas Penel, Sébastien Salas, Mathias Neron, Isabelle Ray-Coquard, François Bertucci, Florence Duffaud

المساهمون: Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Unité de biostatistiques, CRLCC Val d'Aurelle - Paul Lamarque, Institut Curie [Paris], Département de recherche translationnelle, Département d'oncologie médicale, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Institut Gustave Roussy (IGR), Pôle chirurgical et interventionnel [Gustave Roussy], Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Medical Oncology Unit, S. Camillo-Forlanini Hospital, Service d’Oncologie Médicale [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Département d'oncologie médicale [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Centre Léon Bérard [Lyon], Service d'Oncologie Médicale, Département d'oncologie Médicale, Département de Recherche Translationnelle, Université de Lille-UNICANCER, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)

المصدر: Annals of Surgical Oncology
Annals of Surgical Oncology, Springer Verlag, 2019, ⟨10.1245/s10434-019-08097-x⟩
Annals of Surgical Oncology, 2019, ⟨10.1245/s10434-019-08097-x⟩

مصطلحات موضوعية: Adult, Male, Alkylating Agents, medicine.medical_specialty, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Breast Neoplasms, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Metastasis, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Phyllodes Tumor, Surgical oncology, medicine, Humans, Neoplasm Metastasis, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, business.industry, Hazard ratio, Retrospective cohort study, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Confidence interval, 3. Good health, Surgery, Radiation therapy, Oncology, Chemotherapy, Adjuvant, Surgical Procedures, Operative, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, France, Sarcoma, business

الوصف: Metastatic phyllodes tumors have poor prognosis with median overall survival of 11.5 months. The objective of this study is to identify prognostic factors and the best options for management of metastatic malignant phyllode tumors (MMPTs). A multicentric retrospective study, including cases of MMPT from 10 sarcoma centers, was conducted. The primary end-point was overall survival (OS), and the secondary end-point was the clinical benefit of chemotherapy (CBCT) rate. 51 MMPT patients were included. Median time from diagnosis to metastatic recurrence was 13 months. Management of MMPT consisted in surgery of the metastatic disease for 16 patients (31.3%), radiation therapy of the metastatic disease for 15 patients (31.9%), and chemotherapy for 37 patients (72.5%). Median follow-up was 62.1 months [95% confidence interval (CI) 31–80 months]. Median OS was 11.5 months (95% CI 7.5–18.7 months). On multivariate analysis, two or more metastatic sites [hazard ratio (HR) 2.81, 95% CI 1.27–6.19; p = 0.01] and surgery of metastasis (HR 0.33, 95% CI 0.14–0.78; p = 0.01) were independently associated with OS. The CBCT rate was 31.4% and 16.7% for the first and second lines. Polychemotherapy was not superior to single-agent therapy. Alkylating-agent-based chemotherapy, possibly associated with anthracyclines, was associated with a better CBCT rate than anthracyclines alone (p = 0.049). The results of this study emphasize the impact of the number of metastatic sites on survival of MMPT patients and the leading role of metastasis surgery in MMPT management. If systemic therapy is used, it should include alkylating agents, which are associated with a better clinical benefit.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ba96f9d9ea661ef2685a33df02f917Test
https://doi.org/10.1245/s10434-019-08097-xTest

المؤلفون: Kinnunen, Eeva-Maija, Mosorin, Matti-Aleksi, Perrotti, Andrea, Ruggieri, Vito G., Svenarud, Peter, Dalén, Magnus, Onorati, Francesco, Faggian, Giuseppe, Santarpino, Giuseppe, Maselli, Daniele, Dominici, Carmelo, Nardella, Saverio, Musumeci, Francesco, Gherli, Riccardo, Mariscalco, Giovanni, Masala, Nicola, Rubino, Antonino S., Mignosa, Carmelo, de Feo, Marisa, Della Corte, Alessandro, Bancone, Ciro, Chocron, Sidney, Gatti, Giuseppe, Juvonen, Tatu, Biancari, Fausto

المساهمون: Oulu University Hospital Oulu, CHU Pontchaillou Rennes, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Karolinska University Hospital Stockholm, University Hospital of Verona, Paracelsus Medizinische Privatuniversität = Paracelsus Medical University (PMU), St Anna Hospital, S. Camillo-Forlanini Hospital, University Hospitals Leicester, Morgagni-Pierantoni Hospital, University of Naples Federico II = Università degli studi di Napoli Federico II

المصدر: ISSN: 1053-0770.

مصطلحات موضوعية: Cardiac surgery, classification, complication, coronary artery bypass grafting, [SDV]Life Sciences [q-bio]

الوصف: International audience ; Objective The authors aimed to validate the European Multicenter Study on Coronary Artery Bypass Grafting (E-CABG) classification of postoperative complications in patients undergoing coronary artery bypass grafting (CABG). Design Retrospective, observational study. Setting University hospital. Participants A total of 2,764 patients with severe coronary artery disease. Complete baseline, operative, and postoperative data were available for patients who underwent isolated CABG. Interventions Isolated CABG. Measurements and Main Results The E-CABG complication classification was used to stratify the severity and prognostic impact of adverse postoperative events. Primary outcome endpoints were 30-day, 90-day, and long-term all-cause mortality. The secondary outcome endpoints was the length of intensive care unit stay. Both the E-CABG complication grades and additive score were predictive of 30-day (area under the receiver operating characteristics curve 0.866, 95% confidence interval [CI] 0.829-0.903; and 0.876; 95% CI 0.844-0.908, respectively) and 90-day (area under the receiver operating characteristics curve 0.850, 95% CI 0.812-0.887; and 0.863, 95% CI 0.829-0.897, respectively) all-cause mortality. The complication grades were independent predictors of increased mortality at actuarial (log-rank: p<0.0001) and adjusted analysis (p<0.0001; grade 1: hazard ratio [HR] 1.757, 95% CI 1.111-2.778; grade 2: HR 2.704, 95% CI 1.664-4.394; grade 3: HR 5.081, 95% CI 3.148-8.201). When patients who died within 30 days were excluded from the analysis, this grading method still was associated with late mortality (p<0.0001). The grading method (p<0.0001) and the additive score (rho, 0.514; p<0.0001) were predictive of the length of intensive care unit stay. Conclusions The E-CABG postoperative complication classification seems to be a promising tool for stratifying the severity and prognostic impact of postoperative complications in patients undergoing cardiac surgery

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26708697; hal-01259442; https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259442Test; https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259442/documentTest; https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259442/file/Validation%20of%20a%20New%20Classification%20Method%20of%20Postoperative.pdfTest; PUBMED: 26708697

الإتاحة: https://doi.org/10.1053/j.jvca.2015.09.019Test
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259442Test
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259442/documentTest
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259442/file/Validation%20of%20a%20New%20Classification%20Method%20of%20Postoperative.pdfTest

المؤلفون: Minacapelli, Eleonora, Giordano, Andrea, Falautano, Monica, Sangalli, Francesca, Pietrolongo, Erika, Lorefice, Lorena, Cocco, Eleonora, Lugaresi, Alessandra, Comi, Giancarlo, Filippi, Massimo, Martinelli, Vittorio

المساهمون: Biogen Idec, Teva Pharmaceutical Industries, Biogen, Ministry of Health, Fondazione Italiana Sclerosi Multipla, Fondazione Italiana di Ricerca per la SLA, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, A.O. Sant'Antonio Abate, Gallarate, A.O. S. Maria della Misericordia, Udine, S. Camillo Forlanini Hospital, Roma, University and Policlinico of Bari, University of Palermo

المصدر: Journal of the Neurological Sciences ; volume 417, page 117064 ; ISSN 0022-510X

مصطلحات موضوعية: Neurology (clinical), Neurology

الإتاحة: https://doi.org/10.1016/j.jns.2020.117064Test
https://api.elsevier.com/content/article/PII:S0022510X20304019?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0022510X20304019?httpAccept=text/plainTest